Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Carboplatin
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Carboplatin
Teva Pharma GmbH
Tubular Breast Cancer Stage II
1 trial -
Carboplatin
Alaunos Therapeutics
Extensive-Stage Small Cell Lung Cancer
1 trial -
Carboplatin
Hoffmann-La Roche
Breast Neoplasms
1 trial -
Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DS-8201a
Daiichi Sankyo
HER2-expressing endometrial cancer (IHC 3+/2+)
1 trial -
Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ribozar 1 g Pulver zur Herstellung einer Infusionslösung, Datopotamab deruxtecan, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Daiichi Sankyo
Locally Advanced or Metastatic Urothelial Carcinoma
1 trial -
Cardioblate® Surgical Ablation System
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatic Valve Disease
1 trial -
CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx
Cardiol Therapeutics
Recurrent Pericarditis
1 trial -
Cariprazine
AbbVie
Bipolar I Disorder
1 trial -
Cariprazine 0.5 mg capsules, hard, Reagila 6 mg hard capsules, Reagila 4.5 mg hard capsules, Reagila 3 mg hard capsules, Reagila 1.5 mg hard capsules
Gedeon Richter Plc.
Adolescent patient (13-17 years of age) with Schizophrenia
1 trial -
Carrellizumab + Capecitabine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Neoplasms
1 trial -
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion
Vertex Pharmaceuticals (Australia) Pty.
Sickle Cell Disease, Transfusion dependent thalassemia
1 trial -
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-Dependent-Thalassemia
1 trial -
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-dependent β-thalassemia (TDT)
1 trial -
Casimersen
Sarepta Therapeutics
Duchenne Muscular Dystrophy
1 trial -
Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat
Lacuna Pharma Pty Ltd
Metastatic hormone-sensitive prostate cancer with high tumor load
1 trial -
Cediranib
AstraZeneca
Recurrent Glioblastoma
1 trial -
Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE
The George Institute
CHRONIC OMALGIA
1 trial -
CellCept 500 mg film-coated tablets, CellCept 1 g/5 ml powder for oral suspension, Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 500 mg film-coated tablets
Hoffmann-La Roche
Childhood Idiopathic Nephrotic Syndrome
1 trial -
Cemdisiran, Pozelimab
Lacuna Pharma Pty Ltd
Paroxysmal nocturnal hemoglobinuria (PNH)
1 trial -
Cenerimod 4 mg, Cenerimod matching placebo
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenerimod matching placebo, Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenestin 0.3 mg Tablets
Teva Pharma GmbH
Hot Flashes
1 trial -
Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671
Sanofi-aventis Healthcare Pty Ltd
Gaucher's disease type III
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources